Rosetta Genomics Receives Key U.S. Patent Allowance for its Cancer of Origin Diagnostic Assay
April 16 2015 - 9:15AM
Business Wire
Covers method of identifying the tissue of
origin from a tissue sample through measuring the expression levels
of 64 microRNAs
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based assays, FISH testing and other molecular
diagnostics, announces receipt of a Notice of Allowance for U.S.
Patent Application No. 13/856,190, entitled, “Methods and materials
for classification of tissue of origin of tumor samples.”
The allowed patent claims a method for identifying a tissue of
origin of a cancer sample by the expression levels of 64 microRNAs
using a combination of probes attached to a solid substrate, and
employing a classifier algorithm in order to identify the tissue of
origin. This patent specifically covers the second generation of
Rosetta’s Cancer Origin Test™, which uses more markers and
identifies a larger spectrum of cancers than the previous
generation. Further, it is based on microarray technology for
microRNA expression profiling.
“This U.S. patent allowance will provide core protection for one
of our lead products, the Rosetta Cancer Origin Test™, which can
accurately identify the primary tumor type in primary and
metastatic cancer including cancer of unknown or uncertain primary.
By accurately identifying the primary tumor origin, physicians are
able to make more informed decisions, to select the best treatment
choices and to optimize patient outcomes. This is particularly
relevant with the number of new targeted oncology therapies coming
to market,” said Kenneth A. Berlin, President and Chief Executive
Officer of Rosetta Genomics. “Our growing intellectual property
position continues to protect and solidify our global leadership
position in microRNA biomarker technology while providing
additional revenue generating opportunities for us and enhancing
our leadership position in the commercialization of differentiated
and/or proprietary content in the area of personalized
medicine.”
Rosetta Genomics has 42 issued patents, five allowed patents and
45 patents pending worldwide.
About Rosetta Cancer Testing Services
Rosetta Cancer Tests are a series of microRNA-based diagnostic
testing services offered by Rosetta Genomics. The Rosetta Cancer
Origin Test™ can accurately identify the primary tumor type in
primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). The Rosetta Lung Cancer Test™ accurately
identifies the four main subtypes of lung cancer using small
amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately
classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and
oncocytoma. Rosetta’s assays are designed to provide objective
diagnostic data. In the U.S. alone, Rosetta Genomics estimates that
200,000 patients a year may benefit from the Rosetta Cancer Origin
Test™, 62,000 from the Rosetta Kidney Cancer Test™ and 222,000
patients from the Rosetta Lung Cancer Test™. The Company’s assays
are offered directly by Rosetta Genomics in the U.S., and through
distributors around the world. In addition to its proprietary
products, the Company markets the Rosetta Genomics PGxOne™ and EGFR
and KRAS tests for Admera Health. With the recent acquisition of
PersonalizeDx, the company now offers a broader menu of molecular
assays for lung, bladder, prostate and breast cancer patients. For
more information, please visit www.rosettagenomics.com. Parties
interested in ordering these tests can contact Rosetta Genomics at
(215) 382-9000 ext. 309.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. PersonalizeDx’s core
FISH, IHC and PCR-based testing capabilities and partnerships in
oncology and urology provide additional content and platforms that
complement the Rosetta offerings. Rosetta’s and PersonalizeDx’s
cancer testing services are commercially available through the
Philadelphia, PA- and Lake Forest, CA-based CAP-accredited,
CLIA-certified labs, respectively.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including without limitation,
statements that the patent allowance will provide core protection
for the Rosetta Cancer Origin Test™ and statements relating to the
benefits of the Rosetta Cancer Origin Test™, constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including those risks more fully discussed in the "Risk
Factors" section of Rosetta’s Annual Report on Form 20-F for the
year ended December 31, 2014 as filed with the SEC. In
addition, any forward-looking statements represent Rosetta’s views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Rosetta does
not assume any obligation to update any forward-looking statements
unless required by law.
Rosetta GenomicsKen Berlin, President & CEO(609)
419-9003investors@rosettagenomics.comorInvestor:LHAAnne
Marie Fields(212) 838-3777afields@lhai.comorBruce Voss(310)
691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Sep 2023 to Sep 2024